pfizer china - Search News

Order byBest matchMost fresh

Pfizer Strikes Deal With China's 3SBio

Pfizer in deal with China's 3SBio to license cancer drug candidate, take equity stake

Swiss food giant Nestle is refocusing on the group's core business after straying into segments like health supplements that "weakened the fabric of the organisation," CEO Laurent Freixe was quoted as...

· 2d · on MSN

· 2d

Pfizer Inc. (PFE) Inks $6 Billion Cancer Drug Licensing Agreement with China’s 3SBio

· 1d · on MSN

Pfizer Inks Up to $6B Deal to Market 3SBio's Cancer Drug Outside China

Pfizer makes a $6 billion run into a new cancer drug race, 6 months after rival

Pfizer Inc. plans to spend billions of dollars to join the race for a new type of cancer treatment.

· 1d

Chinese biotech firm secures US$6 billion Pfizer deal for cancer drug

· 1d

Pfizer Thinks Bigger With 3SBio Deal

BioPharma Dive1d

Pfizer buys into PD-1/VEGF competition with 3SBio deal

Pfizer will pay China’s 3SBio $1.25 billion up front to access a cancer drug that could rival Akeso and Summit’s closely watched immunotherapy ivonescimab.

Fierce Biotech2d

Pfizer pays 3SBio $1.25B for PD-1xVEGF bispecific, joining red-hot race with BioNTech, Merck

Pfizer has joined the PD-1xVEGF bispecific gold rush. The Big Pharma is paying 3SBio $1.25 billion upfront for ex-China rights to a clinical candidate, establishing itself as a challenger to BioNTech,

PharmExec1d

Pfizer, 3SBio Forge Licensing Pact for SSGJ-707 to Target Lung, Colorectal, and Gynecologic Cancers

Under terms of the deal, Pfizer will gain rights to develop, manufacture, and commercialize SSGJ-707 outside of China.